Key Insights

Highlights

Success Rate

80% trial completion

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 37/100

Termination Rate

8.3%

1 terminated out of 12 trials

Success Rate

80.0%

-6.6% vs benchmark

Late-Stage Pipeline

8%

1 trials in Phase 3/4

Results Transparency

75%

3 of 4 completed with results

Key Signals

3 with results80% success

Data Visualizations

Phase Distribution

11Total
Not Applicable (6)
P 1 (2)
P 2 (2)
P 4 (1)

Trial Status

Completed4
Not Yet Recruiting3
Recruiting3
Active Not Recruiting1
Terminated1

Trial Success Rate

80.0%

Benchmark: 86.6%

Based on 4 completed trials

Clinical Trials (12)

Showing 12 of 12 trials
NCT07708402Not ApplicableNot Yet RecruitingPrimary

Healing Stigma Through Stories

NCT07645443Not ApplicableRecruiting

FEEL-GOOD: A Multicenter Trial of a Mindfulness-Based Group Therapy in Young Adults With Early Psychosis

NCT07696000Not ApplicableRecruitingPrimary

The Effect of Structured Medical Nutrition Therapy on Systemic Inflammation Index in Patients With Schizophrenia Receiving Antipsychotic Therapy

NCT07674914Phase 1Not Yet RecruitingPrimary

A Cognitive Mobile Intervention for Motivation in Psychotic Disorders

NCT02808533Not ApplicableActive Not RecruitingPrimary

Topiramate and Schizophrenia: Effects on Weight and Psychopathology

NCT07593456Not ApplicableNot Yet RecruitingPrimary

NST-SPARK Open-Label Phase 1 STTR (IGNITE)

NCT04159662RecruitingPrimary

Brain Imaging of Cognition Inn Schizophrenia and Depression

NCT06319170Phase 1CompletedPrimary

Open-label Trial Characterizing the PK of 3 SC Olanzapine Extended-release Formulations in Participants With Schizophrenia/Schizoaffective Disorder

NCT03669640Phase 2TerminatedPrimary

A Study to Assess the Effects of RO6889450 (Ralmitaront) in Participants With Schizophrenia or Schizoaffective Disorder and Negative Symptoms

NCT04512066Phase 2CompletedPrimary

A Trial of the Efficacy and the Safety of RO6889450 (Ralmitaront) vs Placebo in Patients With an Acute Exacerbation of Schizophrenia or Schizoaffective Disorder

NCT02192593Not ApplicableCompletedPrimary

Computerized Cognitive-Behavioral Therapy for Auditory Hallucinations

NCT00224315Phase 4CompletedPrimary

Clozapine-Augmentation With Ziprasidone or Risperidone, a Randomized, Prospective Trial

Showing all 12 trials

Research Network

Activity Timeline